GLP-1 receptor agonist
/GLP-one receptor agonist/
Also known as: glucagon-like peptide-1 receptor agonist, incretin mimetic
Definition
GLP-1 (glucagon-like peptide-1) receptor agonists are molecules that bind to and activate GLP-1 receptors, which are G-protein-coupled receptors located on pancreatic beta cells, intestinal cells, and neurons. These receptors regulate glucose homeostasis and energy balance. When activated, GLP-1 receptors trigger a cascade of signalling events that influence insulin secretion, glucagon suppression, and gastric motility. In research contexts, GLP-1 receptor agonists have been investigated for their effects on metabolic parameters and weight regulation. The class includes both naturally occurring hormones and synthetic peptide analogues designed to mimic or enhance GLP-1's biological activity.
The endogenous GLP-1 hormone is released from intestinal L-cells in response to nutrient intake, particularly glucose and fatty acids. Synthetic GLP-1 receptor agonists are engineered to have extended half-lives compared to the native hormone, which is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). This longer duration allows for less frequent dosing in research and clinical applications. The receptor is expressed in multiple tissues, enabling GLP-1 agonists to exert effects across metabolic, cardiovascular, and neuroendocrine systems.
Research into GLP-1 receptor agonists has explored their mechanisms through in vitro cell studies, animal models, and human clinical trials. These investigations examine receptor occupancy, downstream signalling pathways, and physiological outcomes. Understanding the tissue-specific effects and the interaction between GLP-1 receptors and other receptors (such as GIP receptors in dual agonists) remains an active area of basic and translational research.